BioVaxys Technology Corp. BVAXF

Full chart Compare

Set alert

0.09 USD 0.00 (-1.11%)

At closeNov 10, 2026, 4:00 PM EST

0.09 Day range 0.09

0.0102 52-week range 0.203

YTD: -47.43%
1 year: -54.75%

News

2 months ago newsfilecorp.com BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - BioVaxys Technology Corp. (OTC Pink: BVAXF) (CSE: BIOV) (FSE: 5LB), ("BioVaxys" or the "Company") a clinical-stage…
6 months ago thenewswire.com BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer Unique MRI Study Shows How the Combination Exerts its Effect VANCOUVER, BC – TheNewswire - May 1, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage…
6 months ago thenewswire.com BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the…
6 months ago thenewswire.com BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an…
7 months ago thenewswire.com BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the…
7 months ago thenewswire.com BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of…
7 months ago thenewswire.com BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the…
8 months ago thenewswire.com BioVaxys Announces Application for Management Cease Trade Order Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) announces that it was unable to file its annual…
9 months ago thenewswire.com BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer VANCOUVER, BC – TheNewswire - January 29, 2026 / TheNewswire / - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB)…
9 months ago newsfilecorp.com BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) Study subject Remains in Complete Response for 3 Years Exceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent Chemotherapy Vancouver, British…
10 months ago thenewswire.com BioVaxys 1Q2026 R&D and Collaborative Activity VANCOUVER, BC, January 15th,2026/ - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or the "Company") is pleased to provide an update on 1Q2026 initiatives,…
10 months ago newsfilecorp.com BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology…
10 months ago thenewswire.com 2025 Corporate Review VANCOUVER, BC, December 31st. 2025 / - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of operating…
10 months ago newsfilecorp.com BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology…
11 months ago thenewswire.com BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or "Company") is pleased to announce that Marianne Stanford, PhD, has…
11 months ago thenewswire.com BioVaxys Technology Corp. Closes Debt Settlement Transaction VANCOUVER, BC, November 25, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“ BioVaxys ” or the “ Company ”) announces that, further to its news release dated November 14,…
11 months ago businesswire.com BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement VANCOUVER, British Columbia--(BUSINESS WIRE)--BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has closed its previously announced non-brokered private…
11 months ago thenewswire.com BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement VANCOUVER, BC, November 1 9 , 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“ BioVaxys ” or the “ Company ”) announces that it has closed its previously announced…